The COVID-19 Sentinel Schools Network of Catalonia (CSSNC) project: Associated factors to prevalence and incidence of SARS-CoV-2 infection in educational settings during the 2020-2021 academic year.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2022
Historique:
received: 05 04 2022
accepted: 03 11 2022
entrez: 17 11 2022
pubmed: 18 11 2022
medline: 22 11 2022
Statut: epublish

Résumé

The Sentinel Schools project was designed to monitor and evaluate the epidemiology of COVID-19 in Catalonia, gathering evidence for health and education policies to inform the development of health protocols and public health interventions to control of SARS-CoV-2 infection in schools. The aim of this study was to estimate the prevalence and incidence of SARS-CoV-2 infections and to identify their determinants among students and staff during February to June in the academic year 2020-2021. We performed two complementary studies, a cross-sectional and a longitudinal component, using a questionnaire to collect nominal data and testing for SARS-CoV-2 detection. We describe the results and perform a univariate and multivariate analysis. The initial crude seroprevalence was 14.8% (95% CI: 13.1-16.5) and 22% (95% CI: 18.3-25.8) for students and staff respectively, and the active infection prevalence was 0.7% (95% CI: 0.3-1) and 1.1% (95% CI: 0.1-2). The overall incidence for persons at risk was 2.73 per 100 person-month and 2.89 and 2.34 per 100 person-month for students and staff, respectively. Socioeconomic, self-reported knowledge, risk perceptions and contact pattern variables were positively associated with the outcome while sanitary measure compliance was negatively associated, the same significance trend was observed in multivariate analysis. In the longitudinal component, epidemiological close contact with SARS-CoV-2 infection was a risk factor for SARS-CoV-2 infection while the highest socioeconomic status level was protective as was compliance with sanitary measures. The small number of active cases detected in these schools suggests a low transmission among children in school and the efficacy of public health measures implemented, at least in the epidemiological scenario of the study period. The major contribution of this study was to provide results and evidence that help analyze the transmission dynamic of SARS-CoV-2 and evaluate the associations between sanitary protocols implemented, and measures to avoid SARS-CoV-2 spread in schools.

Identifiants

pubmed: 36395191
doi: 10.1371/journal.pone.0277764
pii: PONE-D-22-10020
pmc: PMC9671345
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0277764

Informations de copyright

Copyright: © 2022 Ganem et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Arch Dis Child. 2022 Mar;107(3):e20
pubmed: 34857510
BMC Med. 2021 Sep 10;19(1):233
pubmed: 34503493
Lancet. 2020 Apr 18;395(10232):1255-1256
pubmed: 32247323
J Infect Dis. 2021 Feb 13;223(3):362-369
pubmed: 33119738
J Korean Med Sci. 2020 Nov 30;35(46):e414
pubmed: 33258334
BMC Public Health. 2021 Jul 19;21(1):1424
pubmed: 34281512
Pediatrics. 2021 Apr;147(4):
pubmed: 33419869
Int J Environ Res Public Health. 2021 Jan 30;18(3):
pubmed: 33573323
Ital J Pediatr. 2021 Jan 09;47(1):6
pubmed: 33422089
J Korean Med Sci. 2020 Apr 06;35(13):e143
pubmed: 32242349
Front Pediatr. 2021 Sep 08;9:754744
pubmed: 34568244
JAMA Pediatr. 2021 Jun 1;175(6):586-593
pubmed: 33480966
Euro Surveill. 2020 Sep;25(38):
pubmed: 32975186
Euro Surveill. 2021 May;26(20):
pubmed: 34018483
Lancet Infect Dis. 2021 Mar;21(3):344-353
pubmed: 33306981
BMC Fam Pract. 2020 Oct 10;21(1):208
pubmed: 33038926
Philos Trans R Soc Lond B Biol Sci. 2021 Jul 19;376(1829):20200261
pubmed: 34053259
Lancet Infect Dis. 2020 Aug;20(8):911-919
pubmed: 32353347
Int J Public Health. 2020 Dec;65(9):1549-1557
pubmed: 33063141
BMC Public Health. 2021 Feb 5;21(1):295
pubmed: 33546644
Lancet Infect Dis. 2021 May;21(5):629-636
pubmed: 33545090
J Korean Med Sci. 2021 Mar 01;36(8):e63
pubmed: 33650338
Euro Surveill. 2020 Sep;25(36):
pubmed: 32914746
Science. 2020 Jun 26;368(6498):1481-1486
pubmed: 32350060
Science. 2021 May 28;372(6545):
pubmed: 33906968
Lancet Public Health. 2021 Sep;6(9):e683-e691
pubmed: 34252364
Euro Surveill. 2021 Feb;26(7):
pubmed: 33602386
BMJ. 2021 Mar 17;372:n616
pubmed: 33731327
BMC Infect Dis. 2018 Jan 10;18(1):29
pubmed: 29321005
PLoS One. 2015 Dec 15;10(12):e0144839
pubmed: 26669757
Pediatr Pulmonol. 2020 Oct;55(10):2576-2586
pubmed: 32790245
JAMA Pediatr. 2021 Feb 1;175(2):143-156
pubmed: 32975552
Pediatrics. 2021 Jul;148(1):
pubmed: 33863845
Lancet Infect Dis. 2020 May;20(5):533-534
pubmed: 32087114
PLoS One. 2021 May 12;16(5):e0251593
pubmed: 33979410
Clin Infect Dis. 2021 Sep 15;73(6):e1261-e1269
pubmed: 33709135
BMJ Open. 2022 Jan 25;12(1):e055649
pubmed: 35078847
Emerg Infect Dis. 2020 Oct;26(10):2465-2468
pubmed: 32673193
Front Public Health. 2021 Aug 04;9:680514
pubmed: 34422743
Exp Biol Med (Maywood). 2021 Feb;246(3):293-297
pubmed: 33210552
Nature. 2008 Apr 10;452(7188):750-4
pubmed: 18401408
Nat Commun. 2021 Feb 3;12(1):777
pubmed: 33536436
JAMA Netw Open. 2021 Sep 1;4(9):e2127168
pubmed: 34581799
Prev Med. 2021 Feb;143:106349
pubmed: 33271236
Int J Environ Res Public Health. 2020 Nov 27;17(23):
pubmed: 33261208
BMJ Open. 2021 Jun 10;11(6):e049876
pubmed: 34112645
J Community Health. 2021 Jun;46(3):457-470
pubmed: 32638198
Front Pediatr. 2021 Mar 16;9:645577
pubmed: 33796490
Lancet. 2020 Aug 22;396(10250):535-544
pubmed: 32645347
Nat Med. 2021 Dec;27(12):2120-2126
pubmed: 34707317

Auteurs

Fabiana Ganem (F)

Centre of Epidemiological Studies on Sexually Transmitted Infections and AIDS of Catalonia (CEEISCAT), Health Department, Government of Catalonia, Badalona, Spain.
Departament de Pediatria, d'Obstetrícia i Ginecologia i de Medicina Preventiva i de Salut Publica, Universitat Autònoma de Barcelona, Bellaterra, Spain.
Institut d'Investigació Germans Trias i Pujol (IGTP), Badalona, Spain.

Anna Bordas (A)

Centre of Epidemiological Studies on Sexually Transmitted Infections and AIDS of Catalonia (CEEISCAT), Health Department, Government of Catalonia, Badalona, Spain.
Institut d'Investigació Germans Trias i Pujol (IGTP), Badalona, Spain.

Cinta Folch (C)

Centre of Epidemiological Studies on Sexually Transmitted Infections and AIDS of Catalonia (CEEISCAT), Health Department, Government of Catalonia, Badalona, Spain.
Institut d'Investigació Germans Trias i Pujol (IGTP), Badalona, Spain.
Spanish Consortium for Research on Epidemiology and Public Health (CIBERESP), Instituto de Salud Carlos III, Madrid, Spain.

Lucia Alonso (L)

Centre of Epidemiological Studies on Sexually Transmitted Infections and AIDS of Catalonia (CEEISCAT), Health Department, Government of Catalonia, Badalona, Spain.
Institut d'Investigació Germans Trias i Pujol (IGTP), Badalona, Spain.

Marcos Montoro-Fernandez (M)

Centre of Epidemiological Studies on Sexually Transmitted Infections and AIDS of Catalonia (CEEISCAT), Health Department, Government of Catalonia, Badalona, Spain.

Andreu Colom-Cadena (A)

Centre of Epidemiological Studies on Sexually Transmitted Infections and AIDS of Catalonia (CEEISCAT), Health Department, Government of Catalonia, Badalona, Spain.
Institut d'Investigació Germans Trias i Pujol (IGTP), Badalona, Spain.

Ariadna Mas (A)

Direcció Assistencial d'Atenció Primària i Comunitària, Institut Català de la Salut, Barcelona, Catalonia, Spain.

Jacobo Mendioroz (J)

Subdirecció general de Vigilància i Resposta a Emergències de l'Agència de Salut Pública de Catalunya, Departament de Salut, Catalonia, Spain.

Laia Asso (L)

Agència de Salut Pública de Catalunya (ASPCAT), Departament de Salut, Generalitat de Catalunya, Catalonia, Spain.

Andres Anton (A)

Microbiology Department, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Universitat Autònoma de Barcelona, Barcelona, Catalonia, Spain.

Tomàs Pumarola (T)

Microbiology Department, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Universitat Autònoma de Barcelona, Barcelona, Catalonia, Spain.

Maria Victoria González (MV)

Microbiology Department, Laboratori Clínic Metropolitana Nord, Hospital Universitari Germans Trias i Pujol, Institut Català de la Salut, Institut D'Investigació en Ciències de La Salut Germans Trias i Pujol (IGTP), Badalona, Catalonia, Spain.

Ignacio Blanco (I)

Microbiology Department, Laboratori Clínic Metropolitana Nord, Hospital Universitari Germans Trias i Pujol, Institut Català de la Salut, Institut D'Investigació en Ciències de La Salut Germans Trias i Pujol (IGTP), Badalona, Catalonia, Spain.

Pere Soler-Palacín (P)

Pediatric Infectious Diseases and Immunodeficiencies Unit, Hospital Universitari Vall d'Hebron, Vall d'Hebron Institut de Recerca, Universitat Autònoma de Barcelona, Barcelona, Catalonia, Spain.

Antoni Soriano-Arandes (A)

Pediatric Infectious Diseases and Immunodeficiencies Unit, Hospital Universitari Vall d'Hebron, Vall d'Hebron Institut de Recerca, Universitat Autònoma de Barcelona, Barcelona, Catalonia, Spain.

Jordi Casabona (J)

Centre of Epidemiological Studies on Sexually Transmitted Infections and AIDS of Catalonia (CEEISCAT), Health Department, Government of Catalonia, Badalona, Spain.
Departament de Pediatria, d'Obstetrícia i Ginecologia i de Medicina Preventiva i de Salut Publica, Universitat Autònoma de Barcelona, Bellaterra, Spain.
Institut d'Investigació Germans Trias i Pujol (IGTP), Badalona, Spain.
Spanish Consortium for Research on Epidemiology and Public Health (CIBERESP), Instituto de Salud Carlos III, Madrid, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH